Unknown

Dataset Information

0

Subtyping of microsatellite instability-high colorectal cancer.


ABSTRACT: BACKGROUND:Patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC) generally have a better prognosis than patients with microsatellite stable (MSS) CRC. However, some MSI-H CRC patients do not gain overall survival benefits from immune checkpoint-blockade treatment. In other words, heterogeneity within the subgroup of MSI-H tumors remains poorly understood. Thus, an in-depth molecular characterization of MSI-H tumors is urgently required. METHODS:Here, we use nonnegative matrix factorization (NMF)-based consensus clustering to define CRC MSI-H subtypes in The Cancer Genome Atlas and a French multicenter cohort GSE39582. CIBERSORT was used to calculate the proportions of 22 lymphocytes in tumor tissue in MSI-H subtypes. RESULTS:MSI-H CRC samples basically clustered into two subgroups (MSI-H1 and MSI-H2). MSI-H1 was characterized by a lower BRAF mutational status, higher frequency of chromosomal instability, global hypomethylation, and worse survival than MSI-H2. Further examination of the immune landscape showed that macrophages of the M2 phenotype were enriched in MSI-H1, which may be associated with poor prognosis in this subgroup. CONCLUSIONS:Our results illustrate the genetic heterogeneity in MSI-H CRCs and macrophages may serve as good targets for anticancer therapy in MSI-H1.

SUBMITTER: Hu W 

PROVIDER: S-EPMC6647262 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Subtyping of microsatellite instability-high colorectal cancer.

Hu Wangxiong W   Yang Yanmei Y   Qi Lina L   Chen Jiani J   Ge Weiting W   Zheng Shu S  

Cell communication and signaling : CCS 20190722 1


<h4>Background</h4>Patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC) generally have a better prognosis than patients with microsatellite stable (MSS) CRC. However, some MSI-H CRC patients do not gain overall survival benefits from immune checkpoint-blockade treatment. In other words, heterogeneity within the subgroup of MSI-H tumors remains poorly understood. Thus, an in-depth molecular characterization of MSI-H tumors is urgently required.<h4>Methods</h4>Here, we use  ...[more]

Similar Datasets

| S-EPMC4580394 | biostudies-other
2007-09-07 | E-TABM-326 | biostudies-arrayexpress
| S-EPMC6088272 | biostudies-literature
| S-EPMC4723875 | biostudies-literature
| S-EPMC3427139 | biostudies-literature
| S-EPMC8192371 | biostudies-literature
| S-EPMC9822542 | biostudies-literature
| S-EPMC4072907 | biostudies-other
| S-EPMC4422840 | biostudies-literature
| S-EPMC9097548 | biostudies-literature